SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                  FORM 10-QSB/A

|X|   Quarterly Report Under Section 13 or 15(d) of the Securities Exchange Act
      of 1934.

                 For the quarterly period ended: March 31, 2003

                                       OR

|_|   Transition Report Under Section 13 or 15(d) of the Securities Exchange Act
      of 1934.

                       For the transition period from: to

                       Commission File Number: 000-030813

                                  AlphaRx, Inc.
                 (Name of Small Business Issuer in its Charter)

          Delaware                                       98-0177440
(State or other jurisdiction of             (I.R.S. Employer Identification No.)
incorporation or organization)

                             10-75 East Beaver Creek
                             Ontario L4B 1B8, Canada
                    (Address of principal executive offices)

       Registrant's telephone number, including area code: (905) 762-0745

        Securities registered pursuant to Section 12(b) of the Act: None

           Securities registered pursuant to Section 12(g) of the Act:
                         Common Stock, $.0001 par value
                                (Title of Class)

Check whether the issuer (1) filed all reports required to be filed by Section
13 or 15(d) of the Securities Exchange Act of 1934 during the past 12 months (or
for such shorter period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90 days. Yes
|X| No |_|

The number of outstanding shares of registrant's Common Stock on May 19, 2003
was 16,844,558.

Transitional Small Business Disclosure Format. Yes |_| No |X|


<PAGE>

                                  ALPHARx, INC.

                                  FORM 10-QSB/A

                                 March 31, 2003

                                TABLE OF CONTENT

DESCRIPTION                                                                 Page

Part I          Financial Information

Item 1          Financial Statements                                        3

                Unaudited Balance Sheets as of March 31, 2003 and 2002      3

                Unaudited Statements of Operations for the three months
                ended March 31, 2003 and 2002                               5

                Unaudited Statements of Operations for the six months
                ended March 31, 2003 and 2002                               6

                Unaudited Statements of Cash Flows for the six months
                ended March 31, 2003 and 2002                               7

                Unaudited Statement of Retained Deficits for the six
                months ended March 31, 2003 and 2002                        8

                Notes to the Financial Statements                           9

Item II         Management's Discussion and Analysis of Financial
                Condition and Results of Operations                         14

Part II         Other Information                                           17

SIGNATURE PAGE                                                              19


2
<PAGE>

PART I - FINANCIAL INFORMATION

ITEM 1 - FINANCIAL STATEMENTS

                                  ALPHARX, INC.
                          (A Development Stage Company)

                                 BALANCE SHEETS
                          AS OF MARCH 31, 2003 and 2002

                                     ASSETS

                                                             March 31   March 31
                                                               2003       2002
CURRENT ASSETS

   Cash                                                                 $  3,723
   Accounts Receivable                                       $    955     14,488
   Prepaid Legal Fees                                          41,402
   Due from Officer                                                83      1,335
   Loan Payable                                                            3,305
   Inventory                                                   97,418     47,856
                                                             --------   --------

     TOTAL CURRENT ASSETS                                     139,858     70,707

PROPERTY, PLANT & EQUIPMENT, at cost

         Less accumulated deprecation of $64,464(note 4)      122,962
                                                             --------
         Less accumulated deprecation of $40,934                         124,223
                                                                        --------

OTHER ASSETS

   Licensing Right                                            230,000
   Investment                                                  20,000     46,408
                                                             --------   --------
                                                              250,000

TOTAL ASSETS                                                 $512,820   $241,338
                                                             ========   ========


3
<PAGE>

                      LIABILITIES AND SHAREHOLDERS' EQUITY

                                                     March 31         March 31
                                                       2003             2002

CURRENT LIABILITIES

   Cash Shortage                                    $     5,829
   Accounts Payable and Accrued Liabilities              23,643     $    34,250
   Notes Payable-Current                                 94,930         318,114
   Salary Payable                                                       154,000
   Accrued Interest                                                      22,166
   Litigation Liabilities                                25,000
   Sales Tax Payable                                        205             787
                                                    -----------     -----------
        TOTAL CURRENT LIABILITIES                       149,607         529,317

LONG-TERM LIABILITIES

   Notes Payable                                         13,553
       TOTAL LONG-TERM LIABILITIES

SHAREHOLDER'S EQUITY

Common Stock, common, $ 0.0001 par value,
   Authorized 100,000,000 shares, issued and
   outstanding 16,844,558 shares (note 5)           $     1,685
   Additional paid-in capital                         3,710,512
   Deficit                                           (3,362,537)
                                                    -----------
Common Stock, common, $0.0005par value,
   Authorized 100,000,000 shares, issued and
   outstanding 11,193,064 shares                                    $     5,596
   Additional paid in capital                                         1,923,330
   Deficit                                                           (2,216,905)
                                                                    -----------
TOTAL SHAREHOLDER'S EQUITY                              349,660        (287,979)
                                                    -----------     -----------
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY          $   512,820     $   241,338
                                                    ===========     ===========


4
<PAGE>

                                  ALPHARX, INC.

                          (A Development Stage Company)

                            STATEMENTS OF OPERATIONS
               FOR THE THREE MONTHS ENDED MARCH 31, 2003 and 2002

                                                                March 31
                                                          2003           2002
                                                          ----           ----

SALES                                                  $     644      $  13,840

COST OF SALES                                                780          9,932
                                                       ---------      ---------

GROSS PROFIT                                                (136)         3,908

SELLING, GENERAL AND ADMINISTRATIVE EXPENSES             294,369        221,389
                                                       ---------      ---------

         LOSS FROM OPERATION                            (294,505)      (217,481)

OTHER INCOME
   Interest Income                                     $       0      $       0
   Other Income                                           10,000
   Exchange Rate Gain                                         63              0
                                                       ---------      ---------
                                                          10,063              0

         LOSS BEFORE INCOME TAXES                       (284,442)      (217,481)

INCOME TAX                                                     0              0
                                                       ---------      ---------

NET LOSS                                               $(284,442)     $(217,481)
                                                       =========      =========


5
<PAGE>

                                  ALPHARX, INC.

                          (A Development Stage Company)

                            STATEMENTS OF OPERATIONS
                FOR THE SIX MONTHS ENDED MARCH 31, 2003 and 2002

                                                                March 31
                                                          2003           2002
                                                          ----           ----
SALES                                                  $   2,498      $  13,840

COST OF SALES                                              2,243          9,932
                                                       ---------      ---------

GROSS PROFIT                                                 255          3,908

SELLING, GENERAL AND ADMINISTRATIVE EXPENSES             562,093        428,720
                                                       ---------      ---------

         LOSS FROM OPERATION                            (561,838)      (424,812)

OTHER INCOME
   Interest Income                                             2
   Other Income                                           10,000
   Exchange Rate Gain                                        682

         LOSS BEFORE INCOME TAXES                       (551,154)      (424,812)

INCOME TAX                                                     0              0
                                                       ---------      ---------

NET LOSS                                               $(551,154)     $(424,812)
                                                       =========      =========


6
<PAGE>

                                  ALPHARX, INC.
                          (A Development Stage Company)

                            STATEMENTS OF CASH FLOWS
                FOR THE SIX MONTHS ENDED MARCH 31, 2003 and 2002

                                                                March 31
                                                            2003         2002
CASH FLOWS FROM OPERATING ACTIVITIES
   Net Loss                                              $(551,154)   $(424,812)
   Depreciation Amount                                      12,132       11,132

   Adjustments to reconcile note income to net cash
     Cash provided by operating activities:
        Changes in assets and liabilities:
           Increase in Accounts Receivable                    (955)     (14,488)
           Increase in Prepaid Legal Fees                  (12,017)
           Increase in Licensing Right                    (230,000)
           Increase in Due from Officer                        (83)      (1,335)
           Increase in Inventory                           (45,277)     (47,856)
           Increase (Decrease) in Accounts Payable          (1,037)       6,472
           Increase in Accrued Interest                                  11,831
           Decrease in Salary Payable                                  (124,000)
           Increase in Sales Tax Payable                       205          787
           Increase in Loan Payable                                      (3,305)
           Increase in Notes Payable-Current                44,135       68,360
           Increase in Notes Payable                        12,029
                                                         ---------    ---------
NET CASH USED BY OPERATIONS ACTIVITIES                   $(772,022)   $(517,214)

CASH FLOWS FROM INVESTING ACTIVITIES
       Increase of Investments                             (20,000)
          Acquisition of Automobiles                       (14,149)
          Acquisition of Machinery & Equipment              (3,843)
                                                         ---------    ---------
NET CASH USED BY INVESTING ACTIVITIES                    $ (37,992)   $       0


CASH FLOWS FROM FINANCING ACTIVITIES
       Proceeds from Issuance of Stock                         152          645
       Increase in Additional Paid-In Capital              813,235      536,551
                                                         ---------    ---------
NET CASH PROVIDEDBY FINANCING ACTIVITIES                 $ 813,387    $ 537,196

NET INCREASE IN CASH                                         3,373       19,982

CASH AS OF September 30, 2002 (2001)                        (9,202)     (16,259)
                                                         ---------    ---------

CASH AND CASH EQUIVALENTS AT END OF PERIOD               $  (5,829)   $   3,723
                                                         =========    =========

SUPPLEMENTARY DISCLOSURE:

The statement of cash flows using indirect method
as defined under Statement of Financial Accounting
Standard of No. 95.


7
<PAGE>

                                  ALPHARX, INC.

                          (A Development Stage Company)

                         STATEMENT OF RETAINED DEFICITS
                FOR THE SIX MONTHS ENDED MARCH 31, 2003 and 2002

RETAINED DEFICITS
                                                      March 31

                                          2003                          2002
                                          ----                          ----

Beginning balance, October 1, 2002    $(2,811,383)   Oct. 1, 2001   $(1,792,093)

Net loss for the period                  (551,154)                     (424,812)
                                      -----------                   -----------

Ending balance, March 31, 2003        $(3,362,537)   Mar. 31, 2002  $(2,216,905)
                                      ===========                   ===========


The accompanying notes are an integral part of this statement


8
<PAGE>

                                 ALPHARX, INC.

                         (A Development Stage Company)

                         NOTES TO FINANCIAL STATEMENTS

                                 MARCH 31, 2003

NOTE 1. INTERIM FINANCIAL INFORMATION

In the opinion of management, the accompanying unaudited financial statements
contain all necessary adjustments, which are of a normal recurring nature, to
present fairly the financial position of AlphaRx, Inc. as of March 31, 2003 and
2002, the results of operations for the six months ended March 31, 2003 and
2002, and the cash flows for the six months ended March 31, 2003 and 2002, in
conformity with generally accepted accounting principles. Operating results for
the six months period ended March 31, 2003 are not necessarily indicative of the
results that may be expected for the entire year ending September 30, 2003 or
future operating periods.

These unaudited interim financial statements should be read in conjunction with
the audited financial statements and related notes contained in AlphaRx's Form
10-KSB/A for the fiscal year ended September 30, 2002.

NOTE 2. FORMATION AND ORGANIZATION OF BUSINESS

ALPHARX, INC. (the Company) was incorporated under the laws of the State of
Delaware on August 8, 1997. The company is an emerging pharmaceutical company
specializing in the formulation of therapeutic products using proprietary drug
delivery technologies. The company was formally known as LOGIC TECH
INTERNATIONAL, INC., and had its corporate name amended during the fiscal year
of 1998.


9
<PAGE>

                                 ALPHARX, INC.

                         (A Development Stage Company)

                         NOTES TO FINANCIAL STATEMENTS

                                 MARCH 31, 2003

NOTE 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

This summary of significant accounting policies of ALPHARX, INC. is presented to
assist in understanding the Company's financial statements. The financial
statements and notes are representations of the Company's management who is
responsible for their integrity and objectivity. These accounting policies
conform to generally accepted accounting principles and have been consistently
applied in the preparation of the financial statements.

Cash and Cash Equivalent

For purpose of these statements, cash equivalent included cash on hand, cash in
bank, and all short-term debt securities purchased with a maturity of three
months or less.

Depreciation

The company's property, plant, and equipment are depreciated using the Straight
Line Method, with recovery period of 3 years & 10 years.

Property and Equipment

Property and equipment are stated at cost. Depreciation is calculated by using
Straight Line Method for financial reporting as well as income tax reporting
purposes at rates based on the following estimated useful lives:

             Automobiles                            5 years
             Machinery and Equipment                7 years
             Furniture and Fixtures                 7 years
             Improvements                          10 years

The company capitalizes expenditures that materially increase assets' lives and
expense ordinary repairs and maintenance to operating as incurred. When assets
are sold or disposed or otherwise fully depreciated, the cost and related
accumulated deprecation are removed from the accounts and any gain or loss is
included in the statement of income and related earnings.


10
<PAGE>

                                  ALPHARX, INC.

                          (A Development Stage Company)

                          NOTES TO FINANCIAL STATEMENTS

                                 MARCH 31, 2003

NOTE 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued.)

Income Taxes

The company is a C Corporation that subjects to accrual of federal tax according
to tax laws. There is no income tax for year ended since the company was under a
development stage and did not have active business operations. The State of
Delaware does not impose tax on corporation net income.

Research and Development (R&D)

All research and development cost were charged to expense for the period ended.
These costs included traveling to explore and evaluate new products and
negotiating marketing rights, products licensing, and various legal and
professional fees incurred for preparation of patent applications. A total of
$155,288 R&D expense had been spent during the interim period.

NOTE 4. PROPERTY, PLANT & EQUIPMENT

                                                        Life Year
Automobiles                               $ 36,216           5
Machinery & Equipments                     137,718           7
Furniture & Fixtures                        11,656           7
Improvements                                 1,836          10
                                          --------
     Less accumulated depreciation          64,464
                                          --------
                                          $122,962
                                          ========

NOTE 5. COMMON STOCK

The Company is authorized to issue 100,000,000 shares of common stock. As of
March 31, 2003, 16,844,558 shares of such common stock had been issued and
outstanding, each share bears a par value of $0.0001.


11
<PAGE>

                                  ALPHARX, INC.

                          (A Development Stage Company)

                          NOTES TO FINANCIAL STATEMENTS

                                 MARCH 31, 2003

NOTE 6. PRIVATE PLACEMENT

The Company did a Private Placement, under which shareholders within the
placement were granted warrants to purchase shares of the Company's authorized
but unissued common stock at $1.10 per share. The private placement was done at
$0.55 per share with one warrant. The warrants expire on November 30, 2003. As
of March 31, 2003, a total of 913,448 shares were issued under the Private
Placement.

NOTE 7. NOTES PAYABLE

At March 31, 2003, the Company has a note payable of $108,483. This note is
unsecured and bears interest at 0%-12% per annum. $94,930 of the notes payable
has been classified as current in the accompanying Balance Sheets because
repayment is anticipated from April 1, 2003 to September 30, 2003.

NOTE 8. LITIGATION LOSS

The Company is a defendant in a lawsuit, filed by a prospective investor
alleging breach of contract, which seeks damages totaling $25,000. Due to the
fact that we had failed to obtain a legal opinion from the Company's counsel,
the entire claim is accrued in the financial statements.


12
<PAGE>

                                  ALPHARX, INC.

                          (A Development Stage Company)

                          NOTES TO FINANCIAL STATEMENTS

                                 MARCH 31, 2003

NOTE 9. COMMITMENTS

Leases

The Company leased its computers until February 31, 2006 and the aggregate
minimum monthly payments due are as follows:

                    Year                      Amount
                    ----                      ------

                    2005                      $341
                    2004                      $1,755
                    2003                      $1,840
                    2002                      $1,499

The Company leased its automobile until October 31, 2006 and the aggregate
minimum monthly payments due are as follows:

                    Year                      Amount
                    ----                      ------

                    2006                      $284
                    2005                      $3,403
                    2004                      $3,403
                    2003                      $3,403
                    2002                      $3,658


13
<PAGE>

ITEM 2: MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION OR PLAN OF
OPERATION

      The following discussion and analysis should be read in conjunction with
the Financial Statements, including the Notes thereto, appearing in this Form
10-QSB/A. Except for the historical information contained herein the foregoing
discussion contains forward-looking statements that involve risks and
uncertainties. Our actual results could differ materially from those projected
in the forward-looking statements discussed herein.

General

      We are a development stage drug delivery company specializing in the
development of innovative therapeutic products for the pharmaceutical and
consumer health care market. Our core competence is in the development of novel
drug formulations for therapeutic molecules or compounds that have exhibited
poor G.I. absorption due to poor solubility or have yet be administerable to the
human body with an acceptable delivery method. Our drug delivery system is
versatile and offers significant flexibility in the development of suitable
dosage formulations (i.e. oral, topical or parenteral) to meet the requirements
of specific drug molecules. Our primary activities since inception (August 7,
1997) have been, in addition to research and development, establishing our
offices and research facilities, recruiting personnel, filing patent
applications, developing a business strategy and raising capital.

      We acquired the world-wide exclusive commercialization rights of VT-1 from
Select Therapeutics Inc. in January 2003. Discovered by scientists at the
Hospital for Sick Children, the University Health Network and the University of
Toronto, VT-1 has demonstrated the ability to kill tumor cells that express a
certain receptor (CD77) with great efficiency. Our initial development focus for
VT-1 will target "poor prognosis cancer patients", such as patients diagnosed
with recurrent, advanced brain tumors.

      We have successfully completed the test marketing of Flexogan, a series of
over-the-counter topical analgesics. A national roll-out in Canada are expected
to occur in mid 2003, at which time management anticipates the Company emerging
from the development stage.

      We intend to continue investing in the further development of our drug
delivery technologies and to actively seek collaborators and licensees to
accelerate the development and commercialization of products incorporating our
drug delivery systems. Depending upon a variety of factors, including
collaborative arrangements, available personnel and financial resources, we will
conduct or fund clinical trials on such products and will undertake the
associated regulatory activities.

RESULTS OF OPERATIONS

      The six months of fiscal year 2003 ending March 31, 2003 resulted in a net
loss $551,154 from operations as compared to $424,812 for the corresponding
fiscal 2002 period. The increase


14
<PAGE>

was primarily due to VT-1 acquisition and Flexogan initial production. Salary
expenses were lower due to a voluntary salary reduction by key officers.

Research and Development Expense

      Research and development expense for the six months ended March 31, 2003
was approximately $155,288, compared to approximately $184,023 for the
corresponding fiscal 2002 period. The decrease was primarily due to a voluntary
salary reduction by key scientific officers.

      Our research and development expenses may include costs for scientific
personnel, supplies, equipment, outsourced clinical and other research
activities, consultants, utilities, administrative expenses and an allocation of
corporate costs. The scope and magnitude of future research and development
expenses cannot be predicted at this time for our product candidates in the
early phases of research and development as it is not possible to determine the
nature, timing and extent of clinical trials and studies, the FDA's requirements
for a particular drug and the requirements and level of participation, if any,
by potential partners. As potential products proceed through the development
process, each step is typically more extensive, and therefore more expensive,
than the previous step. Success in development therefore results, generally, in
increasing expenditures. Furthermore, our business strategy involves licensing
certain of our drug candidates to collaborative partners. Depending upon when
such collaborative arrangements are executed, the amount of costs incurred
solely by us will be impacted.

LIQUIDITY AND CAPITAL RESOURCES

      Since inception, we have financed operations principally from the sale of
Common Stock and expect to continue this practice to fund our ongoing
activities.

      We currently do not have sufficient resources to complete the
commercialization of any of our proposed products or to carry out our business
strategy. Therefore, we will likely need to raise substantial additional capital
to fund our operations sometime in the future. We cannot be certain that any
financing will be available when needed. Any additional equity financings may be
dilutive to our existing shareholders, and debt financing, if available, may
involve restrictive covenants on our business.

      We expect to continue to spend capital on:

      1. research and development programs;

      2. preclinical studies and clinical trials;

      3. regulatory processes; and

      4. establishment of our own pilot scale manufacturing and marketing
capabilities or a search for third party manufacturers and marketing partners to
manufacture and market our products for us.

      The amount of capital we may need will depend on many factors, including :

      1. the progress, timing and scope of our research and development
programs;


15
<PAGE>

      2. the progress, timing and scope of our preclinical studies and clinical
trials;

      3. the time and cost necessary to obtain regulatory approvals;

      4. the time and cost necessary to establish our own sales and marketing
capabilities or to seek marketing partners to market our products for us;

      5. the time and cost necessary to respond to technological and market
developments; and

      6. new collaborative, licensing and other commercial relationships that we
may establish.

      The inability to raise capital would have a material adverse effect on the
Company. We currently have no capital commitments other than the payment of rent
on our facilities lease.

CERTAIN FACTORS THAT MAY AFFECT FUTURE RESULTS

      AlphaRx is a development stage company. Certain of the information
contained in this document constitutes "forward-looking statements", including
but not limited to those with respect to the future revenues, our development
strategy, involve known and unknown risks, uncertainties, and other factors
which may cause our actual results, performance or achievements to be materially
different from any future results, performance or achievements expressed or
implied by such forward-looking statements. Such factors include, among others,
the risks and uncertainties associated with a drug delivery company which has
not commercialized our first product, including a history of net losses,
unproven technology, lack of manufacturing experience, current and potential
competitors with significant technical and marketing resources, need for future
capital and dependence on collaborative partners and on key personnel.
Additionally, we are subject to the risks and uncertainties associated with all
drug delivery companies, including compliance with government regulations and
the possibility of patent infringement litigation, as well as those factors
disclosed in our documents filed from time to time with the United States
Securities and Exchange Commission.


16
<PAGE>

PART II: OTHER INFORMATION

ITEM 1 - LEGAL PROCEEDINGS

      Farhad Walji vs. AlphaRx, Inc. and AlphaRx Canada Limited filed in the
Supreme Court of British Columbia on August 23, 2002. Farhad Walji has filed a
claim asking for $25,000 plus interest for allegedly providing $20,000 pursuant
to a subscription agreement to purchase common shares of AlphaRx's stock and
damages resulting from lost opportunity. The Company has denied any liability in
this case and is currently defending this action vigorously. Nonetheless, the
value of the entire claim has been accrued in our financial statements as a
contingent liability.

ITEM 2 - CHANGES IN SECURITIES AND USE OF PROCEEDS

      During the three months ended March 31, 2003, the Company conducted a
private placement and sold an aggregate of 506,263 restricted shares of the
Company's common stock to foreign investors at a price of $0.55 per share for a
total purchase price of $278,445 in reliance on Rule 506 of Regulation D and/or
Section 4(2) of the Securities Act and to persons outside the United States
within the meaning of Regulation S of the Securities Act in a private
transaction that did not involve a public offering. In connection with this
private placement, the Company issued a warrant to purchase a maximum of 506,263
restricted shares of the Company's common stock with an exercise price of $1.10
per share.

      On March 31, 2003, the Company issued an aggregate of 452,500 restricted
shares of its common stock to Michael Lee, Joseph Schwarz, Michael Weisspapir
and Sai Ming Wong for services rendered as officers valued at $0.40 a share in
lieu of cash obligations due under the terms of their employment agreements in
reliance on Rule 506 of Regulation D and/or Section 4(2) of the Securities Act
and to persons outside the United States within the meaning of Regulation S of
the Securities Act in a private transaction that did not involve a public
offering. The Company made this offering based on the following factors: (1) the
issuance was an isolated private transaction by the Company which did not
involve a public offering; (2) the offerees did not resell the stock but
continued to hold it; (3) there were no subsequent or contemporaneous public
offerings of the stock; (4) the stock was not broken down into smaller
denominations; and (5) the negotiations made in connection with the issuance of
the stock took place directly between the offerees and the Company.

ITEM 3 - DEFAULTS UPON SENIOR SECURITIES

      Not applicable.

ITEM 4 - SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

      At the Company's Annual Meeting of Stockholders held on April 15, 2003 the
stockholders of the Company elected the following persons as directors of the
Company to serve until the next


17
<PAGE>

annual meeting of stockholders and until their successors are duly elected and
qualified: Michael Lee, Joseph Schwarz, Ford Moore, David Milroy, Sai Ming Wong.
The results of the voting were as follows:

                                   VOTES FOR          VOTES WITHHELD
                                   ---------          --------------
         Michael Lee               8,233,956                0
         Joseph Schwarz            8,233,956                0
         Ford Moore                8,233,956                0
         David Milroy              8,233,956                0
         Sai Ming Wong             8,233,956                0

      Also at the Annual Meeting, the stockholders ratified the Board's
selection of Deloitte & Touche L.L.P. as the Company's independent auditors for
the fiscal year ending September 30, 2003, with 8,223,956 votes for
ratification, 0 vote against ratification, and 0 abstention.

      Further, the stockholders ratified the Company's 2003 Stock Incentive
Plan, with 8,223,956 votes for ratification, 0 vote against ratification and 0
abstention.

ITEM 5 - OTHER INFORMATION

      None.

ITEM 6 - EXHIBITS AND REPORTS ON FORM 8-K

      (a)   EXHIBITS.

            10.1  2003 Stock Option Plan adopted April 15, 2003 (incorporated by
                  reference to the Form 10-QSB filed on February 21, 2003).

            99.1  Certification by Chief Executive Officer

            99.2  Certification by Chief Financial Officer

      (b)   REPORTS ON FORM 8-K

            No reports on Form 8-K were filed during the quarter ended March 31,
            2003.


18
<PAGE>

                                   SIGNATURES:

      Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.

DATED: May 20, 2003

                                                ALPHARx, INC.


                                                By:  /S/ Michael M. Lee
                                                --------------------------------
                                                Michael M. Lee,
                                                President & Chief Executive
                                                Officer

      Pursuant to the requirements of the Securities Exchange Act of 1934, this
report has been signed by the following persons on behalf of the registrant, in
the capacities, and on the dates, indicated.

DATED: May 20, 2003


   /S/ Michael M. Lee                              /S/ Michael Faye
-----------------------------                   ----------------------
Michael M.  Lee, Director                       Michael Faye, Director


   /S/ Andrew Malion                               /S/ David Milroy
-----------------------------                   ----------------------
Andrew Malion, Director                         David Milroy, Director


  /S/ Ford Moore
-----------------------------
Ford Moore, Director


19
<PAGE>

                                INDEX TO EXHIBITS

EXHIBIT
NO.            DESCRIPTION
-------        -----------

99.1           Certification by Chief Executive Officer

99.2           Certification by Chief Financial Officer


20